Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trimipramine is a tricyclic antidepressant (TCA) primarily used to treat depression. It is structurally similar to imipramine but has more pronounced antihistaminic and sedative properties. Unlike typical TCAs, its mechanism of action is not fully understood; it appears to decrease the reuptake of norepinephrine and serotonin in the brain, thereby increasing their levels and helping restore mental balance[1][3][4]. However, some studies suggest that trimipramine has only weak effects on noradrenergic systems compared to other TCAs, and its clinical efficacy may involve atypical actions on central nervous system pathways[6]. Trimipramine also exhibits anxiolytic and sedative effects, making it useful for patients with comorbid anxiety or sleep disturbances[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trimipramine.